Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Forgent Power Solutions Inc. Class A Common Stock (FPS) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance

Forgent Power Solutions Inc. Class A Common StockTrade
Globus Medical Inc. Class A Common StockTrade

Price performance (Past 24H)

Key statistics

Forgent Power Solutions Inc. Class A Common Stock vs Globus Medical Inc. Class A Common Stock — how do they compare? Forgent Power Solutions Inc. Class A Common Stock trades at $32.13 (market cap $9.93B), while Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B). The key difference: Forgent Power Solutions Inc. Class A Common Stock and Globus Medical Inc. Class A Common Stock are close in size by market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, Forgent Power Solutions Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Forgent Power Solutions Inc. Class A Common Stock for 0 Days and Globus Medical Inc. Class A Common Stock for 0 Days on average.

FPSGMED
Market Cap
$9.93B$10.25B
Volume
7,516,7261,108,124
Sector
IndustrialsHealth
52-Week High
$64.59$96.82
52-Week Low
$27.97$58.33
Typical Hold Time
0 Days0 Days
Enterprise Value
$10.54B$9.76B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Forgent Power Solutions Inc. Class A Common Stock

Forgent Power Solutions (FPS) trades at $36.17, down 2.48% on the day, following a strong earnings-driven rally. The stock shows neutral technical signals with support at $35 and resistance at $37. Recent Q2 2026 earnings beat expectations with EPS of $0.25 versus $0.24 expected, continuing a pattern of quarterly outperformance. The company reported record $3 billion backlog and strong data center demand driving growth.

FPS presents significant upside potential with analyst consensus target of $55.20 (52.9% upside) and 85.7% buy ratings. However, high valuation multiples (P/E 120.57, P/S 6.21) and negative 2025 net income of -$6.17M create valuation concerns. Key risks include execution on $3B backlog and potential overvaluation amid AI infrastructure hype.

Globus Medical Inc. Class A Common Stock

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FPS
100% Buy0% Sell
Avg holding period · 0 Days
GMED
100% Buy0% Sell
Avg holding period · 0 Days

Top news

Latest headlines on both assets

About Forgent Power Solutions Inc. Class A Common Stock

Forgent Power Solutions designs and manufactures electrical distribution equipment, including transformers, switchgear, transfer switches, and prefabricated power systems, for data centers, the power grid, and industrial facilities, manufacturing across multiple product categories in-house through a network of manufacturing campuses in US.

Read more on FPS →

About Globus Medical Inc. Class A Common Stock

Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.

Read more on GMED →